For appointments
Visit Website for more Information
Telemedicine Consult - Dr. Gish
Schedule Telemedicine Consult with Dr. Gish
Telemedicine Consult Services via Folsom Gastromed
Telemedicine Consult Services
WHO:
Dr. Gish is a Hepatologist specializing in all forms of liver disease, liver cancer and liver transplant. Dr. Gish has partnered with TeleMed2U to provide telemedicine consultative services for patients with liver disease.
WHAT:TeleMed2U is a telemedicine-based multi-specialty clinical practice increasing access to specialist providers providing, “healthcare anywhere and everywhere.” The telemedicine consultation will be conducted through our HIPAA and HITECH compliant platform. Connectivity testing will be done in advance to ensure you can connect via our telemedicine platform. Following the consultation, a clinical note will be provided including a summary of your liver consultation with Dr. Gish and his consultative recommendations.
COST:Payment will be processed through an online secure transaction portal. The fees for consultative services are:
- Initial 60 minute consultation per patient: $500.00
- Follow Up 30 minute consultation per patient: $300.00
If you’d like to continue, please click Next to complete the form and we will contact you to schedule connectivity testing. During the test you will have the opportunity to determine the method of providing medical records, discuss appointment availability as well as discuss any additional questions that you have. If you are a healthcare facility interested in services, please complete the form and we can discuss the options that are right for you and your patients.
Powered by
Report from an Expert Consultation on the Evidence for Early Treatment of HCV in the United States
February 3, 2017
Full Meeting Report
By: Richard Wolitski, Ph.D., Director, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services and Corinna Dan, R.N., M.P.H., Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services
In September 2016 HHS hosted a multi-stakeholder meeting, Expert Consultation on the Evidence for Early Hepatitis C Treatment in the United States to identify barriers to accessing hepatitis C treatment and potential strategies for ensuring that people who are infected can get the recommended treatment. This meeting focused specifically on the perspectives, data, and experiences that inform health care policies and practices. It did not tackle the issues, perspectives, and experiences of the pharmaceutical industry. A total of 34 healthcare experts participated including payers, academic researchers, hepatitis advocates, and federal partners.
While several treatments that cure over 90% of individuals with hepatitis C virus (HCV) are now available, a host of challenges and data gaps exist that pose barriers to expanding care to all those in need of treatment. The two-day consultation featured presentations and facilitated discussion on topics including:
- The cost and benefits of early HCV treatment,
- Barriers to accessing HCV direct-acting antiviral agents (DAAs),
- Best practices and effective health care delivery models, and
- Business and other innovative strategies that may improve HCV treatment access.
Participants described HCV treatment access challenges and opportunities that exist at systems, organizational, governmental, and provider levels, and discussed strategies to improve national efforts to address them. Specific key issues and potential actions were discussed such as:
- Payer (e.g., state Medicaid agencies, private insurers) restrictions on HCV treatments,
- Cost and price of DAAs,
- Availability of HCV surveillance and real-world treatment outcome data,
- Health care system capacity for treating HCV, and
- The role of expanded HCV screening (e.g., increasing screening rates, expanding screening recommendations).
Participants highlighted that in order to maximize the potential benefits of these new, curative DAAs, changes in attitude, education, awareness, policy and practice will be needed. Accurate and relevant data are required to help inform decision making and understand the strategies and policies can further support the systems changes needed to best meet the needs of patients with chronic HCV and the healthcare providers and systems that serve them.
This consultation reflects ongoing efforts by HHS to engage with diverse stakeholders, continue to build partnerships and collaboration among federal and nonfederal entities, and work to prevent new infections, reduce deaths and improve the health of people living with viral hepatitis, and reduce viral hepatitis health disparities in the United States.
Slide Presentations
HCV Treatment Access in the United States: Needs vs. Reality
Brian R. Edlin, MD, Chief Medical Officer, National Center HIV, Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
Societal Benefits of HCV Treatment
Jagpreet Chhatwal, PhD, Senior Scientist, Institute for Technology Assessment, Assistant Professor, Harvard Medical School
Center for Medicaid Services and HCV Treatment
John Coster, PhD, RPh, Director, Division of Pharmacy, Center for Medicaid & CHIP Services, Centers for Medicare & Medicaid Services
Working to Improve Access to HCV Treatment
Kevin Costello, JD, Senior Associate Director and Litigation Director, Center for Health Law Policy Innovation, Harvard Law School Stacey Trooskin, MD, PhD, Director of Viral Hepatitis Programs, Philadelphia FIGHT Community Health Centers
HCV Cost Trends and Cost Effectiveness
Benjamin Linas, MD, MPH, Assistant Professor of Medicine and Epidemiology, Boston University, Director HIV Epidemiology and Outcomes Research Unit, Section of Infectious Diseases, Boston Medical Center
Focus on the Payer Perspective
Steve Miller, MD, MBS, Senior Vice President & Chief Medical Officer, Express Scripts